HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY 41-8543

structure in first source

Networked: 14 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - BAY 41-8543: 14
  - Oxazines: 9
    - Morpholines: 6
      - BAY 41-8543: 14

Experts

1.	Stasch, Johannes-Peter: 5 articles (05/2017 - 01/2002)
2.	Loof, Tanja: 3 articles (09/2015 - 09/2011)
3.	Mika, Alice: 3 articles (09/2015 - 09/2011)
4.	Peters, Harm: 3 articles (09/2015 - 09/2011)
5.	Neumayer, Hans-H: 2 articles (09/2015 - 09/2011)
6.	Fulkerson, Mary-Beth K: 2 articles (04/2013 - 12/2011)
7.	Gellar, Michael A: 2 articles (04/2013 - 12/2011)
8.	Kline, Jeffrey A: 2 articles (04/2013 - 12/2011)
9.	Watts, John A: 2 articles (04/2013 - 12/2011)
10.	Evgenov, Oleg V: 2 articles (01/2013 - 12/2007)

Related Diseases

1.	Pulmonary Hypertension 05/02/2017 - "Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension." 12/01/2007 - "We tested whether inhalation of novel dry-powder microparticle formulations containing sGC stimulators (BAY 41-2272, BAY 41-8543) or an sGC activator (BAY 58-2667) would produce selective pulmonary vasodilation in lambs with acute pulmonary hypertension. " 06/30/2012 - "The decreases in pulmonary arterial pressure in response to iv injections of sodium nitroprusside, sodium nitrite, and BAY 41-8543 were not different in rats with monocrotaline-induced pulmonary hypertension and rats with chronic nitrite therapy when compared to responses in animals in which pulmonary arterial pressure was increased with U46619. "
2.	Ureteral Obstruction 09/01/2011 - "Rats were randomly assigned to unilateral ureteral obstruction and unilateral ureteral obstruction plus BAY 41-8543 (10 mg/kg body weight daily). " 09/01/2011 - "We analyzed the action of the specific soluble guanylate cyclase stimulator BAY 41-8543 on the renal recovery phase in rats with unilateral ureteral obstruction after obstruction was relieved. " 07/01/2012 - "After 5-day unilateral ureteral obstruction female and male rats were assigned to obstruction relief alone or obstruction relief plus 7-day treatment with the soluble guanylate cyclase stimulator BAY 41-8543. " 09/01/2011 - "Soluble guanylate cyclase stimulation by BAY 41-8543 increases cyclic guanosine monophosphate production and subsequently enhances renal recovery after unilateral ureteral obstruction relief through an array of pathways. "
3.	Hypertension (High Blood Pressure) 01/01/2002 - "This study investigates the acute effects of BAY 41-8543 on haemodynamics in anaesthetized rats and dogs, its long-term effects in conscious hypertension rat models and its antiplatelet effects. " 01/01/2002 - "In a low NO, high renin rat model of hypertension, BAY 41-8543 prevented the increase in blood pressure evoked by L-NAME and reveals a kidney protective effect. " 01/01/2018 - "Nine healthy Landrace pigs and 7 pigs with DOCA-induced hypertension and LV concentric hypertrophy were acutely instrumented to measure LV end-diastolic pressure-volume relationships (EDPVRs) at baseline and during intravenous infusion of BAY 41-8543 (1 and 3 μg·kg-1·min-1 for 30 min, respectively). "
4.	Uremia 09/01/2015 - "Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia." 09/01/2015 - "This study investigates the effects of biological sex and nitric oxide-independent soluble guanylate cyclase (sGC) stimulator BAY 41-8543 on aortic remodeling in experimental mild uremia. "
5.	Septic Shock (Toxic Shock Syndrome) 04/01/2017 - "The results of the present study indicate that BAY 41-8543 effectively reduces PVR and increases CO in septic shock, through inhaled or intravenous routes of administration."

Related Drugs and Biologics

1.	Soluble Guanylyl Cyclase
2.	Nitric Oxide (Nitrogen Monoxide)
3.	3- (4- Amino- 5- cyclopropylpyrimidine- 2- yl)- 1- (2- fluorobenzyl)- 1H- pyrazolo(3,4- b)pyridine
4.	Desoxycorticosterone Acetate (DOCA)
5.	15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
6.	NG-Nitroarginine Methyl Ester (L-NAME)
7.	Monocrotaline
8.	Solvents
9.	Sodium Nitrite
10.	Renin

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Intravenous Infusions
4.	Oral Administration